CCEP vs COKE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: COKE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CCEP and COKE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CCEP and COKE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Coca-Cola Europacific Partners makes, packages, sells and delivers non-alcoholic ready-to-drink beverages under licence from The Coca-Cola Company and a handful of partner brand owners. Its portfolio spans Coca-Cola, Coca-Cola Zero Sugar, Fanta, Sprite, Schweppes, Monster Energy, Costa Coffee ready-to-drink, Powerade, Capri-Sun, Vitaminwater, Smartwater and, in Australia and the Pacific, the former Amatil brands. The territory list runs across Western Europe (Great Britain, Germany, Spain, France, Belgium, the Netherlands, Portugal, Norway, Sweden, Iceland and smaller markets) plus an Asia Pacific segment built from the 2021 acquisition of Coca-Cola Amatil, which brought Australia, New Zealand, Indonesia, Papua New Guinea and Fiji, and the 2024 purchase of a 60% stake in Coca-Cola Beverages Philippines alongside Aboitiz Equity Ventures. Around ~39,000 employees run the plants, warehouses and route-to-market fleets that reach several hundred million consumers. Ownership is concentrated: Olive Partners, tied to the Daurella family, holds roughly ~36%, and The Coca-Cola Company itself holds roughly ~17%.

Full CCEP guide

Coca-Cola Consolidated (Nasdaq: COKE) is the largest independent bottler and distributor of Coca-Cola products in the United States. It makes, packages, sells, and delivers sparkling drinks like Coca-Cola, Sprite, and Diet Coke plus still beverages such as water, sports drinks, tea, and juice across roughly 14 states, serving more than 65 million consumers. It is a distinct company from The Coca-Cola Company (KO), which owns the brands and concentrate; Consolidated operates under franchise territory agreements to produce and distribute those brands locally, so its economics are driven by case volume, pricing, and the cost of aluminum, plastic, sweeteners, and freight rather than by global brand royalties.

Full COKE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CCEP drivers: Asia Pacific scale, with the Philippines as the swing factor; Revenue growth management rather than volume heroics.
• COKE drivers: Scale as the largest US Coca-Cola bottler; Pricing plus volume growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Currency is the first thing a US shareholder should understand: CCEP reports in euros while the Nasdaq line quotes in dollars, so a weaker euro compresses reported dollar returns even when the underlying business is fine, and the group also carries Australian dollar, sterling, rupiah and peso translation exposure. For COKE, the biggest risk is input-cost volatility.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CCEP if you believe its drivers more; COKE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CCEP and COKE guides.

CCEP. Reported figures are in euros and the conversion to dollars moves with the exchange rate, so a headline US revenue number of ~$24.4bn against a euro base of ~EUR 21.4bn is an artifact of translation rather than of trading. Roughly ~20.9x trailing earnings is a persistent discount to The Coca-Cola Company, which is the market pricing the structural difference between owning a brand and owning the trucks and plants that carry it. Beta near ~0.48 and a payout ratio under half of earnings are what give the shares their defensive character.

COKE. As of early July 2026 the stock traded around $196 with a market cap near $12 billion and a trailing P/E of roughly 27, above its own multi-year average in the high teens. The dividend yield is modest at well under 1 percent, reflecting a business that returns more cash through buybacks than dividends.

Headline figures (approximate, August 2026): CCEP shows revenue (ttm) ~EUR 21.4bn (about ~$24.4bn), operating profit / margin (ttm) ~EUR 2.9bn, margin ~13.5%, net income / diluted eps (ttm) ~EUR 2.0bn, ~EUR 4.44 per share, market cap / enterprise value ~$47.5bn / ~$59.9bn; COKE shows revenue (fy2025) ~$7.2B, revenue (ttm) ~$7.5B, q1 2026 net sales ~$1.85B, q1 2026 eps ~$1.68.

CCEP and COKE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CCEP and COKE exposure against your real portfolio. It is not an investment adviser.